Literature DB >> 3545116

Comparison of ketanserin and metoprolol in the treatment of essential hypertension.

S G Sheps, A Schirger, P K Zachariah, L D Fisher, R E Spiekerman, F J Araas, J B Collins, D C Agerter.   

Abstract

Ketanserin, a serotonin receptor antagonist (S2), lowered blood pressure in patients with essential hypertension; at three months 72% (13/18) had a successful reduction in pressure. No marked orthostatic changes were noted. Older patients responded better when standing. Compared with metoprolol, ketanserin provided no significant difference in response at three months. With ketanserin, the heart rate was reduced only in the supine position, whereas it was reduced in the supine and standing positions with metoprolol. Response to ketanserin could not be predicted from baseline renin, aldosterone, or cortisol levels in blood, nor were there any changes in these factors or in plasma hydroxyindole levels with therapy. Ketanserin was generally well tolerated. Cholesterol values were significantly reduced with ketanserin, and there were no adverse hematologic or biochemical changes. Ketanserin should have a significant role in managing hypertension.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3545116

Source DB:  PubMed          Journal:  Arch Intern Med        ISSN: 0003-9926


  4 in total

Review 1.  Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease.

Authors:  R N Brogden; E M Sorkin
Journal:  Drugs       Date:  1990-12       Impact factor: 9.546

2.  Ketanserin in the treatment of diabetes-associated hypertension.

Authors:  C Beretta-Piccoli
Journal:  Drugs       Date:  1988       Impact factor: 9.546

3.  Serotonin metabolism and age-related effects of antihypertensive therapy with ketanserin.

Authors:  R Amstein; N Fetkovska; F Ferracin; A Pletscher; F R Bühler
Journal:  Drugs       Date:  1988       Impact factor: 9.546

4.  Hypertensive patients with Raynaud's phenomenon or intermittent claudication and their treatment with ketanserin.

Authors:  J C van Oene
Journal:  Drugs       Date:  1988       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.